Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Thoracic Oncology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1556-0864(16)30246-5PMID 27198274
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).

  2026cites this paper
• Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression

  2025cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

  2024cites this paper
• Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer

  2024cites this paper
• Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer

  2024cites this paper
• Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

  2023cites this paper
• The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC.

  2023cites this paper
• Minimal residual disease in EGFR-mutant non-small-cell lung cancer

  2022cites this paper
• Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism

  2022cites this paper
• Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer

  2022influential citation
• Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience

  2022cites this paper
• Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report

  2022cites this paper
• Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

  2022cites this paper
• Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

  2022cites this paper
• Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

  2021cites this paper
• Risk factors for immune-related adverse events: what have we learned and what lies ahead?

  2021cites this paper
• Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.

  2021cites this paper
• Moving beyond Epidermal Growth Factor Receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.

  2021cites this paper
• Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors

  2021cites this paper
• Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors

  2021cites this paper
• Lung cancer

  2021cites this paper
• Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.

  2021cites this paper
• Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

  2021cites this paper
• Toxicity Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Patients with Lung Cancer: A Systematic Review and Network Meta-Analysis.

  2021cites this paper
• Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

  2021cites this paper
• Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.

  2021cites this paper
• A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance

  2021cites this paper
• Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

  2021cites this paper
• A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

  2021cites this paper
• Combining

  2020cites this paper
• Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?

  2020cites this paper
• Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

  2020cites this paper
• Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy.

  2020cites this paper
• Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

  2020cites this paper
• Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?

  2020cites this paper
• Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.

  2020cites this paper
• Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

  2020cites this paper
• Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

  2020cites this paper
• Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

  2020cites this paper
• Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer

  2020cites this paper
• Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

  2020cites this paper
• Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

  2020cites this paper
• Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

  2020cites this paper
• Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

  2020cites this paper
• Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.

  2020cites this paper
• Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review.

  2020cites this paper
• A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

  2020cites this paper
• Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer

  2020cites this paper
• Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

  2020cites this paper
• Mechanisms of resistance to osimertinib

  2020cites this paper
• Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.

  2020cites this paper
• Clinical burden of immune checkpoint inhibitor-induced pneumonitis.

  2020cites this paper
• Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench

  2020cites this paper
• The efficacy and safety of osimertinib in treating nonsmall cell lung cancer

  2020cites this paper
• Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations

  2020cites this paper
• Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer

  2020influential citation
• Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer

  2020cites this paper
• Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?

  2020cites this paper
• First Line Combination Immunotherapy for Metastatic Non-Small-Cell Lung Cancer.

  2020cites this paper
• TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

  2020cites this paper
• NF-κB and Its Role in Checkpoint Control

  2020cites this paper
• The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

  2020cites this paper
• Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation

  2020cites this paper
• RET‐rearranged non‐small‐cell lung cancer and therapeutic implications

  2019cites this paper
• A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

  2019cites this paper
• Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)

  2019cites this paper
• Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?

  2019cites this paper
• Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma

  2019cites this paper
• Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

  2019cites this paper
• Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

  2019cites this paper
• Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

  2019cites this paper
• Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.

  2019cites this paper
• Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

  2019cites this paper
• Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

  2019cites this paper
• Durvalumab for the treatment of non-small cell lung cancer

  2019cites this paper
• Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

  2019cites this paper
• Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

  2019cites this paper
• Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

  2019cites this paper
• OTT_A_200615 4955..4973

  2019cites this paper
• Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects

  2019cites this paper
• Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

  2019cites this paper
• Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

  2019cites this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

  2019cites this paper
• EGFR Targeted Therapy

  2019cites this paper
• Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

  2019cites this paper
• Emerging drugs for EGFR-mutated non-small cell lung cancer

  2019cites this paper
• A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer

  2019cites this paper
• Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

  2019cites this paper
• A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.

  2019cites this paper
• Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

  2019cites this paper
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

  2019cites this paper
• Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?

  2019cites this paper
• A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

  2019cites this paper
• Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

  2019cites this paper
• Targeted Therapies for Lung Cancer

  2019cites this paper
• Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

  2019cites this paper
• Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer.

  2019cites this paper
• Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma.

  2019cites this paper
• Targeting Programmed Cell Death ‐1 (PD‐1) and Ligand (PD‐L1): A new era in cancer active immunotherapy

  2019cites this paper
• Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

  2019cites this paper